Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

Multiple Sclerosis

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Cochrane Database Syst Rev.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G

doi: 10.1002/

Multiple Sclerosis

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

JAMA.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, MSBase Study Group

doi: 10.1001/jama.

RECOMMENDED

Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Lancet Neurol.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N

doi: 10.1016/S1474-4422(19)30151-6.

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Ther Adv Neurol Disord

Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG).

doi: 10.1177/17562864211039648

Multiple Sclerosis

Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis

Mult Scler.

Sotirchos ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, Glaister J, Filippatou A, Ogbuokiri E, Feldman S, Kwakyi O, Risher H, Crainiceanu C, Pham DL, Van Zijl PC, Mowry EM, Reich DS, Prince JL, Calabresi PA, Saidha S

doi: 10.1177/

Multiple Sclerosis

World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application

Mult Scler.

McDonell J, Costello K, Laurson-Doube J, Rijke N, Giovannoni G, Banwell B, Baneke P

doi: 10.1177/1352458519898340.

Multiple Sclerosis

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis

Eur J Neurol.

Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J

doi: 10.1111/ene.13936.

SPECIAL REPORT

Multiple Sclerosis

Related content

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis

World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis